On the other hand, immune checkpoint inhibitors act by removing the inhibitory pathways that block antitumor T cells, and it is well documented that their efficacy is directly proportional to tumor mutational burden, which generates cancer-specific neo-epitopes recognized by CD8+/CD4+ T cells [9]. This evidence concerns the gene CD8A and neoplasm.